Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
First identified and characterized by researchers at the University of Zagreb, BPC-157 has been the subject of extensive preclinical investigation spanning over two decades
That is 20 units on a U-100 syringe from a 50 mg vial mixed in 2 mL
The anti-catabolic effects become particularly valuable during the caloric deficit created by Tirzepatide therapy
With the combination, weve had amazing results with patients who have canceled knee replacement surgeries, had back pain for 10 years who no longer have back pain, with healing their own injuries or recovering from pain
BPC-157 is a perfect real-world example
When multiplied by the standard 2026 non-QP conversion factor of $33.4009 , the national unadjusted office payment settles at $14.36
US$ 25.53
US$ 25.78
US$ 27.01
US$ 26.34
US$ 24.20
